FY2020 EPS Estimates for Sarepta Therapeutics Inc. (SRPT) Boosted by Analyst
Sarepta Therapeutics Inc. (NASDAQ:SRPT) – Stock analysts at Wedbush boosted their FY2020 EPS estimates for shares of Sarepta Therapeutics in a note issued to investors on Monday. Wedbush analyst H. Behanna now anticipates that the firm will post earnings per share of $2.37 for the year, up from their prior estimate of $2.33. Wedbush currently has a “Outperform” rating and a $72.00 target price on the stock.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same quarter in the prior year, the firm earned ($0.87) earnings per share.
A number of other equities analysts have also recently weighed in on the stock. Cowen and Company reissued a “market perform” rating on shares of Sarepta Therapeutics in a research report on Monday, August 15th. Janney Montgomery Scott raised shares of Sarepta Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $30.00 to $65.00 in a research report on Monday, September 19th. William Blair reaffirmed an “outperform” rating and set a $88.00 price target on shares of Sarepta Therapeutics in a research report on Sunday, October 2nd. Jefferies Group reaffirmed an “underperform” rating and set a $7.00 price target on shares of Sarepta Therapeutics in a research report on Saturday, June 25th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $23.00 price target on shares of Sarepta Therapeutics in a research report on Monday, July 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Sarepta Therapeutics has a consensus rating of “Buy” and a consensus target price of $58.44.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/fy2020-eps-estimates-for-sarepta-therapeutics-inc-srpt-boosted-by-analyst.html
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 6.64% during midday trading on Tuesday, reaching $53.82. The company’s stock had a trading volume of 3,626,559 shares. Sarepta Therapeutics has a 1-year low of $8.00 and a 1-year high of $63.73. The stock has a 50 day moving average of $41.90 and a 200-day moving average of $25.76. The company’s market capitalization is $2.58 billion.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. TIAA CREF Investment Management LLC raised its position in Sarepta Therapeutics by 5.5% in the first quarter. TIAA CREF Investment Management LLC now owns 216,707 shares of the company’s stock worth $4,230,000 after buying an additional 11,334 shares in the last quarter. Franklin Resources Inc. bought a new position in Sarepta Therapeutics during the first quarter worth approximately $13,506,000. BlackRock Fund Advisors raised its position in Sarepta Therapeutics by 2.2% in the first quarter. BlackRock Fund Advisors now owns 1,661,818 shares of the company’s stock worth $32,439,000 after buying an additional 36,371 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its position in Sarepta Therapeutics by 2.5% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 1,068,913 shares of the company’s stock worth $20,865,000 after buying an additional 25,799 shares in the last quarter. Finally, State Street Corp raised its position in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares in the last quarter. Institutional investors and hedge funds own 65.29% of the company’s stock.
In related news, VP Jayant Aphale sold 35,000 shares of the firm’s stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the transaction, the vice president now owns 21,490 shares in the company, valued at $1,074,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Edward M. Md Kaye sold 40,179 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $2,410,740.00. Following the transaction, the chief executive officer now owns 117,162 shares in the company, valued at approximately $7,029,720. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.